Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -9.67% is 75% above its 5-year average of -38.52%, near the high end of its 5-year range (-105.50%–-8.98%).
9.03% above its 12-month average of -10.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -2.90%.
RETURN ON ASSETS (ROA)
-9.67%
RETURN ON ASSETS (ROA) AVG TTM
-10.63%
RETURN ON ASSETS (ROA) AVG 3Y
-19.71%
RETURN ON ASSETS (ROA) AVG 5Y
-38.52%
RETURN ON ASSETS (ROA) AVG 10Y
-39.66%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+9.03%
CURRENT VS 3Y AVG
+50.93%
CURRENT VS 5Y AVG
+74.90%
CURRENT VS 10Y AVG
+75.62%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
+63.29%
vs the sector median at left
Ardelyx, Inc.
Market Cap
$837.43M
Return on Assets (ROA)
-9.67%
TTM Avg
-10.63%
3Y Avg
-19.71%
5Y Avg
-38.52%
Market Cap
$844.28M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$852.55M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$819.44M
Return on Assets (ROA)
-8.70%
TTM Avg
6.33%
3Y Avg
-16.09%
5Y Avg
-46.82%
Market Cap
$856.30M
Return on Assets (ROA)
-32.46%
TTM Avg
-61.56%
3Y Avg
-55.11%
5Y Avg
-72.90%
Market Cap
$812.20M
Return on Assets (ROA)
10.76%
TTM Avg
17.66%
3Y Avg
20.82%
5Y Avg
23.86%
Market Cap
$867.60M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$786.48M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ardelyx, Inc. (ARDX) | $837.43M | -9.67% | -10.63% | -19.71% | -38.52% |
| Alumis Inc. (ALMS)vs › | $844.28M | -78.30% | -72.68% | -105.45% | -105.45% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -24.96% | -29.43% | -70.30% | -70.30% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -8.70% | 6.33% | -16.09% | -46.82% |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | -32.46% | -61.56% | -55.11% | -72.90% |
| InMode Ltd. (INMD)vs › | $812.20M | 10.76% | 17.66% | 20.82% | 23.86% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -23.15% | -12.59% | -25.36% | -32.38% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -18.03% | -7.81% | -4.40% | -1.35% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -5.26% | 0.19% | -3.34% | -3.22% |
ROA
-9.7%
ROE
-37.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -12.28% |
| 2024-12-31 | -8.98% |
| 2023-12-31 | -22.20% |
| 2022-12-31 | -35.36% |
| 2021-12-31 | -105.50% |
| 2020-12-31 | -46.79% |
| 2019-12-31 | -36.55% |
| 2018-12-31 | -49.80% |
| 2017-12-31 | -40.75% |
| 2016-12-31 | -52.73% |
| 2015-12-31 | -25.33% |
| 2014-12-31 | -2.83% |
| 2013-12-31 | -15.30% |
| 2012-12-31 | -25.83% |
